Aclarion Announces First Commercial Agreement in Michigan
14 août 2024 08h08 HE
|
Aclarion, Inc.
Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan Agreement Expands Nociscan Access to John Keller, MD, a Leading Neurosurgeon and Aclarion Medical Advisor,...
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
13 août 2024 09h07 HE
|
Aclarion, Inc.
Vitality is a top 4 Provider of Private Medical Insurance in the UK.Aclarion now has Payer Coverage From 3 of the 4 Largest Private Health Insurers in the UK.Nearly 60% of all Patients With Private...
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
09 juil. 2024 07h00 HE
|
Aclarion, Inc.
Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care...
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
26 juin 2024 08h30 HE
|
Aclarion, Inc.
AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First...
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
04 mars 2024 08h00 HE
|
Aclarion, Inc.
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting...
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
05 févr. 2024 08h00 HE
|
Aclarion, Inc.
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical...
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
17 janv. 2024 08h00 HE
|
Aclarion, Inc.
Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine This new product release expands accessibility of Nociscan on the worldwide MR market Builds...
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
08 janv. 2024 08h00 HE
|
Aclarion, Inc.
Partnership aims to include Aclarion’s surgical decision support technology within ATEC’s AlphaInformatiX platform to better inform spine surgery Aclarion’s Nociscan is the first augmented...
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
27 nov. 2023 08h00 HE
|
Aclarion, Inc.
Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel...
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
08 nov. 2023 08h00 HE
|
Aclarion, Inc.
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care....